Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

NASDAQ:LPCN opened at $3.54 on Friday. The firm’s 50-day moving average is $3.79 and its 200-day moving average is $4.53. The company has a market cap of $18.94 million, a price-to-earnings ratio of -4.66 and a beta of 1.42. Lipocine has a 52-week low of $2.91 and a 52-week high of $11.79.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC raised its holdings in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. 9.11% of the stock is currently owned by institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.